Vandetanib

Tyrosine kinase inhibitor; Inhibits VEGFR1, KDR, FLT-4, EGFR, FGFR, ABL, RET, and SRC

Vandetanib

Tyrosine kinase inhibitor; Inhibits VEGFR1, KDR, FLT-4, EGFR, FGFR, ABL, RET, and SRC

From: 110 USD
Catalog #
73532_C
Tyrosine kinase inhibitor; Inhibits VEGFR1, KDR, FLT-4, EGFR, FGFR, ABL, RET, and SRC

Overview

Vandetanib is a multi-kinase inhibitor targeting primarily receptor tyrosine kinases, such as vascular endothelial growth factor receptors (VEGFR1, KDR, and FLT4), epidermal growth factor receptor (EGFR), and fibroblast growth factor receptor (FGFR; Morabito et al.). It most potently inhibits KDR with an IC₅₀ of 40 nM. It also inhibits non-receptor tyrosine kinases such as RET, ABL, and SRC as well as several serine/threonine kinases (Carlomagno et al.; Hennequin et al.; Kiselyov et al.; Levinson & Boxer).

CANCER RESEARCH
· Inhibits tumor growth in mouse xenograft models, including RET/PTC papillary thyroid carcinoma and lung carcinoma (Hennequin et al.; Carlomagno et al.).
· Inhibits angiogenesis, cell growth, and metastasis in numerous cancer cell lines (Morabito et al.; Wedge et al.).
Alternative Names
CH 331; ZD 6474; Zactima
Cell Type
Cancer Cells and Cell Lines
Species
Human, Mouse, Rat, Non-Human Primate, Other
Area of Interest
Cancer
CAS Number
443913-73-3
Chemical Formula
C₂₂H₂₄BrFN₄O₂
Molecular Weight
475.4 g/mol
Purity
≥ 98%
Pathway
Tyrosine Kinase
Target
ABL, EGFR, FGFR, FLT4, KDR, RET, SRC, VEGFR1

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
Vandetanib
Catalog #
73532
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Vandetanib
Catalog #
73532
Lot #
All
Language
English

Resources and Publications

Educational Materials (2)

Publications (6)

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. Levinson NM and Boxer SG PloS one 2012

Abstract

Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protein. The Abl inhibitors imatinib, nilotinib and dasatinib are currently used to treat CML, but resistance to these inhibitors is a significant clinical problem. The kinase inhibitor bosutinib has shown efficacy in clinical trials for imatinib-resistant CML, but its binding mode is unknown. We present the 2.4 Å structure of bosutinib bound to the kinase domain of Abl, which explains the inhibitor's activity against several imatinib-resistant mutants, and reveals that similar inhibitors that lack a nitrile moiety could be effective against the common T315I mutant. We also report that two distinct chemical compounds are currently being sold under the name bosutinib"�
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Morabito A et al. The oncologist 2009

Abstract

Vandetanib is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis: vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and REarranged during Transfection tyrosine kinase activity. Phase I clinical trials have shown that vandetanib is well tolerated as a single agent at daily doses textless or =300 mg. In the phase II setting, negative results were observed with vandetanib in small cell lung cancer, metastatic breast cancer, and multiple myeloma. In contrast, three randomized phase II studies showed that vandetanib prolonged the progression-free survival (PFS) time of patients with non-small cell lung cancer (NSCLC) as a single agent when compared with gefitinib or when added to chemotherapy. Rash, diarrhea, hypertension, fatigue, and asymptomatic QTc prolongation were the most common adverse events. Antitumor activity was also observed in medullary thyroid cancer. Four randomized phase III clinical trials in NSCLC are exploring the efficacy of vandetanib in combination with docetaxel, the Zactima in cOmbination with Docetaxel In non-small cell lung Cancer (ZODIAC) trial, or with pemetrexed, the Zactima Efficacy with Alimta in Lung cancer (ZEAL) trial, or as a single agent, the Zactima Efficacy when Studied versus Tarceva (ZEST) and the Zactima Efficacy trial for NSCLC Patients with History of EGFR-TKI chemo-Resistance (ZEPHYR) trials. Based on a press release by the sponsor of these trials, the PFS time was longer with vandetanib in the ZODIAC and ZEAL trials; the ZEST trial was negative for its primary superiority analysis, but was successful according to a preplanned noninferiority analysis of PFS. Ongoing phase II and III clinical trials will better define the appropriate schedule, the optimal setting of evaluation, and the safety of long-term use of vandetanib.
1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2. Kiselyov AS et al. Chemical biology & drug design 2007

Abstract

Novel derivatives of 1,2,4-triazoles are described as potent ATP-competitive inhibitors of vascular endothelial growth factor receptors I and II (VEGFR-1/2). A number of compounds display VEGFR-2 inhibitory activity comparable to that of Vatalanib and Vandetanib in both homogenous time-resolved fluorescence enzymatic and cellular assays. Several active molecules feature high intrinsic permeability (textgreater30 x 10(-5) cm/min) across Caco-2 cell monolayer.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.